Radiation and Tiselizumab with RCHOP for Bulky Follicular Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II clinical trial investigates the effectiveness of combining radiation therapy with Tiselizumab and R-CHOP chemotherapy in patients with previously untreated bulky follicular lymphoma. Patients receive radiation therapy followed by a regimen of Tiselizumab and R-CHOP, with treatment response assessed through PET/CT scans after specific cycles. The study aims to evaluate the safety and efficacy of this combined approach in improving patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed CD20 positive (+) follicular lymphoma, grade 1, 2, or 3a，bulky disease (Mass diameter ≥ 7 cm)
* Have had no prior systemic treatment for lymphoma
* Meeting Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria for initiation of treatment
* Age 18-75 years
* ECOG Performance Status of 0-2 .Stage II, III, or IV by Ann Arbor staging system.
* Demonstrate adequate organ function as defined below; all screening labs to be obtained within 28 days prior to registration.

  1. Hematological: WBC≥3.5×109/L, Platelets ≥ 75×109/L,Absolute Neutrophil Count (ANC) ≥ 1.0×109/L，Hemoglobin (Hgb) ≥ 80 g/L
  2. Renal: Calculated creatinine clearance ≥ 50 mL/min
  3. Hepatic: Bilirubin ≤ 1.5 × upper limit of normal (ULN), AST/ALT ≤ 2.5×ULN
* Females of childbearing potential must be willing to abstain from vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study and for 6 months after the last dose of study drug(s). Males able to father a child must be willing to abstain
* Life expectancy ≥6 months
* Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study

Exclusion Criteria:

* Known active central nervous system lymphoma or leptomeningeal disease,
* Evidence of diffuse large B-cell transformation
* Grade 3b FL
* Concurrent malignancy or malignancy within the last 3 years (except for ductal breast cancer in situ, non-melanoma skin cancer, prostate cancer not requiring treatment, and cervical carcinoma in situ) whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen are not eligible for this trial
* Known history of human immunodeficiency virus (HIV), or active hepatitis C Virus, or active hepatitis B Virus infection, or any uncontrolled active significant infection, including suspected or confirmed John Cunningham (JC) virus infection，any class 3 (moderate) or class 4 (severe) cardiac disease as defined by the New York Heart Association functional classification. Or left ventricular ejection fraction \<50%;
* Known history of human immunodeficiency virus (HIV), or active hepatitis C Virus, or active hepatitis B Virus infection, or any uncontrolled active significant infection
* Known pneumonia associated with idiopathic pulmonary fibrosis, machine (for example, occlusive bronchiolitis), history of drug induced pneumonia, or screening during the chest computed tomography (CT) showed active pneumonia
* Have serious neurological or psychiatric history, can't normal study, including dementia, epilepsy, severe depression and mania
* Patients who were deemed by the investigator to be ineligible for enrollment

Where it's running

• Tianjin Cancer Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Huilai Zhang, MD,PhD
• Email: 18526812877@163.com
• Phone: 02223359337

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• MK-1045 and Rituximab in Follicular Lymphoma

  This study tests whether adding MK-1045 to rituximab can help people with follicular lymphoma after standard therapy.

  Recruiting at 38 sites Phase 2/3 Merck Sharp & Dohme LLC · Duarte, California and 37 other locations · NCT07634471

• Mosunetuzumab and Zeprumetostat in Follicular Lymphoma

  This study tests whether a combination of Mosunetuzumab and Zeprumetostat can help adults with follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07555470

• Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma

  This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07299149

• LY4584180 with rituximab for adults with previously treated B‑cell lymphomas

  This trial will test LY4584180 together with rituximab in adults with previously treated B‑cell lymphomas to see if it is safe, reaches useful levels in the blood, and can help control the disease.

  Recruiting at 21 sites Phase 1 Eli Lilly and Company · Scottsdale, Arizona and 45 other locations · NCT07226843

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.